CVD

Global Medical Laser Systems Market Research Report 2023 with Competitive Analysis of Alcon, Artivion, Bausch + Lomb, Biolase, Boston Scientific, Candela, Cynosure, Iridex, Nova Eye, and Stryker - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 21, 2023
Health, Medical Devices, Other Health, Disease, Computer, Brain, Prevalence, CVD, Cardiology, Dye, Surgeon, Mortality, Urology, Stroke, Patient, Multimedia, Virtual reality, Laser, Cardiovascular disease, Multi, Heart, Elective surgery, Solid, Solid-state laser, COVID-19, Blood, ASAPS, Night vision, Neurosurgery, Person, Diagnosis, Biochemistry, Macular degeneration, Dermatology, Society, Physician, General surgery, Robotics, Diabetic retinopathy, Paratriathlon, Dentistry, Telemetry, Glaucoma, 3D printing, Medical imaging, Medical device, Nursing, Gynaecology, Hospital, Ophthalmology, Others

The global medical laser systems market is anticipated to reach US$3.86 billion in 2023, growing at a CAGR of 14.47% during 2022-2026

Key Points: 
  • The global medical laser systems market is anticipated to reach US$3.86 billion in 2023, growing at a CAGR of 14.47% during 2022-2026
    The global medical laser systems market exhibits a diverse landscape characterized by fragmentation.
  • Anticipated growth in the demand for aesthetic laser procedures, particularly in developing nations, is expected to drive the expansion of the medical laser systems market.
  • North America has emerged as the dominant player in the global medical laser systems market.
  • Global Medical Laser Systems Market: An Analysis
    Global Medical Laser Systems Market by Product Type (Solid State Lasers, Diode Lasers, Gas Lasers and Dye Lasers)
    Global Medical Laser Systems Market by Application (Dermatology, Ophthalmology, Dentistry, Urology, Gynecology, Cardiology, and Others)
    Global Medical Laser Systems Market by End User (Specialty Clinics, Hospitals, Ambulatory Surgery Centers and Others)
    Global Medical Laser Systems Market: Product Type Analysis
    Global Medical Laser Systems Market: Application Analysis
    Global Medical Laser Systems Market: End User Analysis

CVD Equipment Corporation Announces Participation in 12th Annual NYC Summit

Retrieved on: 
Thursday, November 16, 2023
Mining, Minerals, Mobile, Wireless, Natural Resources, Other Science, Research, Engineering, Chemicals, Plastics, Other Energy, EV, Electric Vehicles, Science, Automotive Manufacturing, Automotive, Aerospace, Oil, Gas, Semiconductor, Manufacturing, Satellite, Alternative Energy, Energy, Nanotechnology, Maritime, Air, Transport, Other Technology, General Automotive, Environment, Hardware, Electronic Design Automation, Technology, Fairchild Recording Equipment Corporation, CVV, CVD, Cryptocurrency

CVD Equipment Corporation (NASDAQ: CVV ), a leading provider of chemical vapor deposition, thermal and physical vapor transport process equipment, announced today it will be joining 14 other companies in collectively hosting the 12th Annual NYC Summit investor conference, being held Tuesday, December 12th at Mastro’s New York.

Key Points: 
  • CVD Equipment Corporation (NASDAQ: CVV ), a leading provider of chemical vapor deposition, thermal and physical vapor transport process equipment, announced today it will be joining 14 other companies in collectively hosting the 12th Annual NYC Summit investor conference, being held Tuesday, December 12th at Mastro’s New York.

Global Graphene and 2D Materials Research Report 2024 with Market Forecasts to 2034 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 16, 2023
Technology, Batteries, Chemicals, Plastics, Manufacturing, Attention, Market, Research, Rhenium disulfide, Electronics, Quantum, Rhenium diselenide, SWOT, Lubricant, 2D, Clothing, CVD, MXenes, Boron nitride, Original equipment manufacturer, Filtration, Graphene, Carbon fibers, Rhenium

The Global Market for Graphene and 2D Materials 2024-2034 is the most comprehensive and up-to date report on graphene and 2D materials currently available.

Key Points: 
  • The Global Market for Graphene and 2D Materials 2024-2034 is the most comprehensive and up-to date report on graphene and 2D materials currently available.
  • This in-depth graphene market report provides a comprehensive analysis of the global graphene industry.
  • The Global Market for Graphene and 2D Materials 2024-2034 contains:
    Assessment of graphene by market including applications, key benefits, market megatrends, market drivers for graphene, technology drawbacks, competing materials, potential consumption of graphene to 2034 and main players.
  • Assessment of graphene materials (CVD graphene, graphene nanoplatelets, graphene oxide, etc), intermediate products (graphene masterbatches, dispersions, etc) and final products with graphene embedded (e.g.

CVD Equipment Corporation Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Mining, Minerals, Natural Resources, Other Manufacturing, Other Energy, Utilities, Oil, Gas, Engineering, Chemicals, Plastics, Alternative Energy, Automotive Manufacturing, Energy, Aerospace, Science, Manufacturing, Mobile, Wireless, Research, Other Defense, Semiconductor, Contracts, HVAC, Satellite, Nanotechnology, Green Technology, Maritime, Defense, Air, Environment, Transport, Other Technology, Hardware, Technology, Machinery, Machine Tools, Metalworking & Metallurgy, Investment, Electronics, CVV, Marketing, Eastern Time Zone, CVD, Operating cost, Growth, Digital Equipment Corporation, Knowledge, Silicon, Overalls, Cryptocurrency, Video game

CVD Equipment Corporation (NASDAQ: CVV), today announced its financial results for the third quarter ended September 30, 2023.

Key Points: 
  • CVD Equipment Corporation (NASDAQ: CVV), today announced its financial results for the third quarter ended September 30, 2023.
  • Emmanuel Lakios, President and CEO of CVD Equipment Corporation, commented, “As previously communicated, our order and revenue levels have historically fluctuated, which is often typical in the highly cyclical process equipment industry.
  • Orders for the third quarter were $4.1 million driven by continued demand in the aerospace sector.
  • Backlog as of September 30, 2023 of $16.6 million, a decrease from $18.8 million at June 30, 2023.

LIB Therapeutics Announces Completion of the Global Phase 3 LIBerate Program of Lerodalcibep, a Novel Third-Generation PCSK9 Inhibitor in Development for Cardiovascular Disease

Retrieved on: 
Tuesday, November 14, 2023
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Managed Care, Health, Clinical Trials, Marketing, Liberation, Cardiovascular disease, MBBS, FH, European Medicines Agency, Patient, Food, Therapy, PCSK9, CVD, Pharmaceutical industry

LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company developing Lerodalcibep, a novel, third-generation PCSK9 inhibitor for patients at very high and high risk of cardiovascular disease (CVD), today announced completion of LIBerate-CVD and LIBerate-HR, the final two registration-enabling Phase 3 trials for patients with CVD or at very high and high risk of CVD.

Key Points: 
  • LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company developing Lerodalcibep, a novel, third-generation PCSK9 inhibitor for patients at very high and high risk of cardiovascular disease (CVD), today announced completion of LIBerate-CVD and LIBerate-HR, the final two registration-enabling Phase 3 trials for patients with CVD or at very high and high risk of CVD.
  • These two trials are part of the registration-enabling Phase 3 LIBerate Program which includes four key studies of 2,387 patients dosed for up to 52 weeks, with >2,200 patients continuing in an open-label extension study of 72 weeks.
  • “The global Phase 3 LIBerate program for Lerodalcibep is a large and comprehensive registration-enabling package and includes a diverse global population of patients with CVD, without CVD but at very high and high risk for CVD, and heterozygous and homozygous familial hypercholesterolemia (FH) which should support a broad label upon approval,” said David Kallend, MBBS, Chief Medical Officer of LIB Therapeutics.
  • “We look forward to working with regulators to submit a biologics license application to the Food and Drug Administration and marketing authorization application to the European Medicines Agency in 1H 2024.”

Front End of the Line Semiconductor Equipment Market size to increase by USD 7.56 billion from 2023 to 2028 | Allwin21 Corp., Applied Materials Inc., ASML and more among key companies- Technavio

Retrieved on: 
Thursday, December 14, 2023
IDM, Lam Research, Stepper, Society of Vacuum Coaters, SUSS, Hitachi, Silicon, Professional corporation, Sumitomo Corporation, USD, Memory, Line, CVD, Applied Materials, Growth, SE, ASML, ECM, Foundry, Generic drug, Semiconductor, Endura, Geography

NEW YORK, Dec. 14, 2023 /PRNewswire/ -- The front end of the line semiconductor equipment market is expected to grow by USD 7.56 billion from 2023 to 2028.

Key Points: 
  • NEW YORK, Dec. 14, 2023 /PRNewswire/ -- The front end of the line semiconductor equipment market is expected to grow by USD 7.56 billion from 2023 to 2028.
  • The growth of the advanced consumer electronics industry is notably driving the front-end of the line semiconductor equipment market.
  • Front End Of The Line Semiconductor Equipment Market 2024-2028: Company Analysis
    Applied Materials Inc.: The company offers front end of the line semiconductor equipment such as Endura, Alta, Axcela, Aera4, and Aeris-S.
  • View PDF Free Sample Report
    Front End Of The Line Semiconductor Equipment Market 2024-2028: Key Highlights
    The US - semiconductor capital spending market size is estimated to grow at a CAGR of 5.31% between 2023 and 2028.

The American Diabetes Association Releases the Standards of Care in Diabetes--2024

Retrieved on: 
Monday, December 11, 2023
Epidemiology, AID, Standard of care, Infection, PPC, Gestational diabetes, Diagnosis, CVD, Disability, Doctor of Philosophy, Mental health, Abridgement, Prediabetes, Diabetes, Knowledge, Webcast, NAFLD, RSV, Endocrinology, Fatty liver disease, Kidney disease, Cardiovascular disease, Fracture, Moyamoya disease, Society, Physician, Public, Hypoglycemia, Waist, Practitioner, PAD, Risk, Pharmacist, GIP, C-peptide, Artificial intelligence, Immunization, Conditional sentence, Section 4, Body mass index, Himawari (satellites), Classification, The Obesity Society, American Diabetes Association, Vaccine, Obesity, American College, Heart failure, COVID-19, Dietary supplement, Nursing, Landscape maintenance, Pharmaceutical industry, Medical device, Dentistry, MD

ARLINGTON, Va., Dec. 11, 2023  /PRNewswire/ -- Today, the American Diabetes Association® (ADA) released the Standards of Care in Diabetes—2024 (Standards of Care), a set of comprehensive and evidence-based guidelines for managing type 1, type 2, gestational diabetes, and prediabetes based on the latest scientific research and clinical trials. It includes strategies for diagnosing and treating diabetes in both youth and adults, methods to prevent or delay type 2 diabetes and its associated comorbidities like cardiovascular disease (CVD) and obesity, and therapeutic approaches aimed at minimizing complications and enhancing health outcomes.

Key Points: 
  • "The latest ADA guidelines present pivotal updates for health care professionals, ensuring comprehensive, evidence-based care for diabetes management.
  • "The ADA's Standards of Care ensures health care professionals, especially our primary care workforce, provide the best possible care to those living with diabetes."
  • The Standards of Care are critical to ensuring the improved treatment of diabetes, a chronic disease that requires continuous care through a well-informed and coordinated health care team.
  • Today, the Standards of Care in Diabetes—2024 is available online and is published as a supplement to the January 2024 issue of Diabetes Care® .

Global Cardiology IT Workflow Solutions Business Report 2023: A $969 Million Market in 2022 - Forecast to 2030 - What to Expect in the Market in the Post COVID-19 Period

Retrieved on: 
Thursday, November 30, 2023
Delivery, Investment, Treatment, Digitalization, CVD, Business case, Digital health, Role, Market, Pharmaceutical industry, Cardiology

Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes

Key Points: 
  • Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes
    Growing Reliance on IT for Clinical Management of Patient Data Brings Cardiology IT Workflow Solutions into a Mainstream Technology in Cardiology Departments Worldwide: Global Spending on Healthcare IT (In US$ Billion) for Years 2021, 2023, 2025 and 2027
    Digitalization to Revolutionize Healthcare & Boost the Role of IT in care Delivery & Management: Global Opportunity for Digital Health (In US$ Billion) for Years 2021, 2023, 2025 and 2027
    Rising Global Burden of Cardiovascular Diseases, Despite Efforts Aimed at Prevention, to Spur Growth in the Market
    Robust Spending on Heart Disease Diagnosis & Treatments Strengthens the Business Case for Investments in Cardiology IT Workflow Solutions: Annual Medical Cost of Cardiovascular Diseases (CVD) in the United States for Years 2020, 2025, 2030 and 2035 (In US$ Billion)

Increasing Wages Will Lead to Healthier Work and Healthier Workers

Retrieved on: 
Wednesday, November 29, 2023
Life expectancy, Social epidemiology, Depression, Conditional sentence, Alcoholic liver disease, Mortality, Cardiovascular disease, Health, CVD, Opioid overdose, Dietary supplement, Nursing

LOS ANGELES, Nov. 29, 2023 /PRNewswire/ -- The Healthy Work Campaign applauds California for leading the way in 2023 to ensure fair, living wages for healthcare and fast-food workers.

Key Points: 
  • LOS ANGELES, Nov. 29, 2023 /PRNewswire/ -- The Healthy Work Campaign applauds California for leading the way in 2023 to ensure fair, living wages for healthcare and fast-food workers.
  • California has recognized that, due to wage stagnation and inflation, the living standard of low-income workers has been in decline for many years.
  • The Healthy Work Campaign has reported previously about the contribution of poor working conditions (including low wages) to the health of workers, especially those without a 4-year college degree, which includes fast-food workers and some healthcare support workers .
  • The Healthy Work Campaign urges other states to follow California's lead, to improve economic justice and the health of low-income workers throughout the U.S.

International Trade Commission Makes Affirmative Preliminary Determination in Trade Cases on Aluminum Extrusions from China, Wiley Rein LLP Reports

Retrieved on: 
Friday, November 17, 2023
Aluminium, Absorption, International trade, United Steelworkers, Commerce, USW, Commission, USITC, CVD, Extrusion

The cases allege that unfairly dumped and subsidized imports of aluminum extrusions are injuring the domestic industry.

Key Points: 
  • The cases allege that unfairly dumped and subsidized imports of aluminum extrusions are injuring the domestic industry.
  • "Today's vote by the Commission takes the domestic industry one step closer to restoring a level playing field to the U.S. aluminum extrusions market."
  • The Commission's affirmative preliminary injury determination paves the way for the Commerce Department to move forward with its investigations.
  • Commerce is expected to issue its preliminary CVD determination in December 2023 and its preliminary AD determination in March 2024.